Francois Brisebois
Stock Analyst at Oppenheimer
(1.78)
# 3,352
Out of 5,113 analysts
81
Total ratings
40.74%
Success rate
-0.46%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics | Maintains: Outperform | $7 → $8 | $3.24 | +146.91% | 3 | Sep 8, 2025 | |
| SVRA Savara | Maintains: Outperform | $5 → $6 | $5.61 | +6.95% | 6 | Aug 15, 2025 | |
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $10.08 | +693.65% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $4.83 | +231.26% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $1.55 | +158.06% | 1 | Jan 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $65 → $72 | $64.18 | +12.18% | 7 | Jan 22, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $36.84 | +65.58% | 6 | Jan 13, 2025 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $11.15 | +151.12% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $21.54 | +39.28% | 8 | Oct 31, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $143 → $163 | $309.92 | -47.41% | 4 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $17.70 | +210.73% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $0.58 | +2,488.44% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $8.44 | -28.91% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $4.36 | +152.29% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $25.24 | -44.53% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $18.63 | +248.90% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $5.42 | +84.50% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $18.42 | +95.44% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $2,500 → $1,500 | $3.14 | +47,670.70% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $1.51 | +357,515.89% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $2.88 | +281.94% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $3.65 | +393.15% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $6.71 | +645.16% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $0.81 | +399,111.43% | 1 | Feb 4, 2020 |
Aquestive Therapeutics
Sep 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $3.24
Upside: +146.91%
Savara
Aug 15, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $5.61
Upside: +6.95%
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $10.08
Upside: +693.65%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $4.83
Upside: +231.26%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $1.55
Upside: +158.06%
Tarsus Pharmaceuticals
Jan 22, 2025
Maintains: Outperform
Price Target: $65 → $72
Current: $64.18
Upside: +12.18%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $36.84
Upside: +65.58%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $11.15
Upside: +151.12%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $21.54
Upside: +39.28%
Praxis Precision Medicines
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $309.92
Upside: -47.41%
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $17.70
Upside: +210.73%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $0.58
Upside: +2,488.44%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $8.44
Upside: -28.91%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $4.36
Upside: +152.29%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $25.24
Upside: -44.53%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $18.63
Upside: +248.90%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $5.42
Upside: +84.50%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $18.42
Upside: +95.44%
Apr 3, 2023
Maintains: Outperform
Price Target: $2,500 → $1,500
Current: $3.14
Upside: +47,670.70%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $1.51
Upside: +357,515.89%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $2.88
Upside: +281.94%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $3.65
Upside: +393.15%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $6.71
Upside: +645.16%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $0.81
Upside: +399,111.43%